In their recent article, [@r1] presented the results of a crystallographic analysis of the binding of tetrabromobisphenol A (TBBPA) and 3-hydroxy-2,2´,4,4´-tetrabromodiphenyl ether (3-OH-BDE-47) to estrogen sulfotransferase (SULT1E1). The authors demonstrated that the tested molecules fit into the same binding pocket as estradiol. However, although the study's methodology and interpretation of the crystallographic analysis provide insight into how binding might occur in isolated and *in vitro* systems, they did not provide evidence that the tested molecules would initiate any biological activity with the relevant estrogen receptors (ERs) or proteins in a human body. For example, the ability of TBBPA to interact with the ER and estrogen-related receptors has been evaluated in recombinant yeast strains, mammalian cell--based assays, and tests developed by the Organisation for Economic Co-operation and Development ([@r2]; [@r3]; [@r4], [@r5]; [@r6], [@r7]; [@r8]). Those studies found that TBBPA either did not interact with ERs or that it acted as a weak ER agonist/antagonist with a potency orders of magnitude below that of natural ER ligands. In addition, the data presented by [@r1] did not include the use of controls to validate the methods. The use of both positive controls (such as diethylstilbestrol and ethinyl estradiol) and a negative control (such as testosterone) would provide validation of the analysis and allow for the quantification and comparison of the two test substances in relation to the binding potentials of the controls.

The authors also speculated about the possible additivity of the various brominated flame retardants and their metabolites and suggested that low-dose exposure to multiple low-affinity binding compounds may result in endocrine disruption. However, none of the data presented directly addressed this point.

It is highly complex, not well understood, and speculative to extrapolate data on inhibition of enzymes such as SULT1E1 in *in vitro* assay systems to endocrine-system modulation of selective gene expression, receptor binding, and activation and the production of adverse effects that would characterize endocrine disruption *in vivo* by additivity of different chemicals competing on the same receptors. Only through a more complete understanding of target tissue dosimetry, potency of interaction of the chemical of interest with the macromolecule of interest (e.g., SULT1E1), and subsequent events can one address the likelihood of *in vivo* additivity.
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